Highlights of ASH 2019
The field of hematology has been rapidly evolving. This continuing medical education activity will discuss new developments in the diagnosis and treatment of malignant and non malignant hematological disorders, as presented at the 2019 Annual Meeting of the American Society of Hematology (ASH). At this one-day course, faculty will share the latest updates in myeloid malignancies, lymphoma, leukemia, multiple myeloma, coagulation disorders, and stem cell transplantation. Through presentations and Q&A, attendees will gain a deeper understanding of emerging treatments available for hematological malignancies and blood disorders and learn how these new therapies can be integrated into daily practice.
|AHN Nursing and Others||$45|
|Non-AHN Nursing and Others||$65|
Onsite registration available
This conference is intended for primary care physicians, hematologists and medical oncologists, fellows, residents, CRNP’s, PA’s, nurses and all other healthcare providers.
- Provide an overview and highlight the cutting edge data presented at the 2018 Annual Meeting of the American Society of Hematology (ASH)
- Identify updates in molecular abnormalities which can be utilized in the diagnosis, prognosis, risk stratification and therapy selection for patients with myeloid malignancies.
- Discuss and assess the relevant clinical trial data in clinical practice which has the potential to improve outcomes in patients with malignant hematologic disorders including Non-Hodgkin's Lymphoma, CLL, and Multiple Myeloma
- Review the updates in sequencing strategies in the era of novel immunotherapies, CAR-T, targeted therapies and stem cell transplantation
- Discuss the latest advances in coagulation and platelet disorders
Self parking only will be validated
Salman Fazal, MD
Assistant Professor, Temple University School of Medicine
Interim Director, Cell Transplantation Program
Allegheny Health Network Cancer Institute
West Penn Hospital
John Lister, MD
Chief, Division of Hematology and
Allegheny Health Network Cancer Institute West Penn Hospital
Allegheny Health Network
West Penn Hospital
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Allegheny General Hospital and West Penn Hospital Allegheny Health Network Cancer Institute. Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Allegheny General Hospital designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 5.75 AMA PRA Category 1 Credit™
- 5.75 Attendance